A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Part of paid clinical trials in Little Rock, Arkansas.

Sponsor
Bristol-Myers Squibb
Study ID
NCT00289627
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this clinical research study is to evaluate the Best Overall Response Rate (BORR), (as per modified WHO criteria) in patients with previously treated melanoma-Stage III (unresectable) or Stage IV melanoma receiving 10 mg/kg of ipilimumab. The safety of this product will also be evaluated.

Key Dates

Start date
Apr 30, 2006
Status verified
Sep 2016
Primary completion
Jul 31, 2007
Completion
Jul 31, 2007

Study Design

Enrollment
155 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ipilimumab (MDX-010, BMS-734016)

Primary Outcome Measure

Evaluate BORR in patients with previously treated Stage III (unresectable) or Stage IV melanoma receiving ipilimumab.

Locations (14)

FacilityCityStateZIPSite coordinators
-Little RockArkansas--
-San FranciscoCalifornia--
-Santa MonicaCalifornia--
-ChicagoIllinois--
-Park RidgeIllinois--
-GoshenIndiana--
-HazardKentucky--
-AlbuquerqueNew Mexico--
-New YorkNew York--
-PortlandOregon--
-GreenvilleSouth Carolina--
-KnoxvilleTennessee--
-DallasTexas--
-CharlottesvillleVirginia--

Find similar trials in Little Rock, AR

By condition
Melanoma
By specialty
OncologySkin cancerDermatology

Related Studies